Key Dates

Related Announcements

• January 25, 2024 - Notice of Change to Receipt Dates for RFA-NS-24-013: Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required) See Notice NOT-NS-24-044 
• October 19, 2023 - Efficacy and Safety of Amyloid-Beta Directed Antibody-Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required). See NOFO RFA-NS-24-013.

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this Notice is to inform applicants of changes in funds available, award budget, and receipt date for RFA-NS-24-013. Specifically, these changes are made to clarify that NIH intends to commit funds starting in FY25, rather than FY24, and to state that the award budget is capped $46.9M Direct Costs (excluding Consortium F&A) over the 7-year project period, rather than $6.7M each year.  The receipt date is being extended until June 14, 2024.

Changes are reflected in italics.  

Currently Reads:

Expiration Date: New Date May 21, 2024 (Original Date: February 21, 2024) per issuance of NOT-NS-24-044

Funds Available and Anticipated Number of Awards

NIH intends to commit the following amounts in FY24: $10,000,000 total budget to fund one award contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award Budget

Direct Costs cannot exceed $6,700,000 per year and need to reflect the actual needs of the proposed project.  

Modified to Read:

Expiration Date: New Date June 14, 2024 (Previous Date: May 20, 2024) per issuance of NOT-NS-24-082

Funds Available and Anticipated Number of Awards

NIH intends to commit up to $10,000,000 in FY25 to fund one award, contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Award Budget 

Application budgets need to reflect the actual needs of the proposed project.  Direct costs (excluding Consortium F&A) cannot exceed $46,900,000 across the proposed 7-year project period.

No other changes to this NOFO.

Inquiries

Please direct all inquiries to:

Rebecca Hommer, MD

National Institute of Neurological Disorders and Stroke (NINDS)

Telephone: 301-827-2257

E-mail: rebecca.hommer@nih.gov